A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.

Also called NCT06258148

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 465 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06258148
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06258148. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-15 (actual); primary completion 2026-01-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TG103
Intervention (Drug)
Placebo
Lead sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06258148
Content hash
00e2f677f523e946d77743130f43b043cf538cee5e329c08bf41a61e554c6b3d